{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:16:10Z","timestamp":1784135770673,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00228-024-03794-3","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T15:50:33Z","timestamp":1734969033000},"page":"279-290","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness of rivaroxaban plus aspirin versus aspirin alone in patients with stable coronary artery disease or peripheral artery disease: a systematic review"],"prefix":"10.1007","volume":"81","author":[{"given":"Jalal","family":"Arabloo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahid","family":"Makhtoumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Mollaei","family":"Sadiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Rezapour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"3794_CR1","unstructured":"GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403 (10440)2100\u201332"},{"key":"3794_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.4103\/ijpvm.IJPVM_224_18","volume":"10","author":"S Gupta","year":"2019","unstructured":"Gupta S, Epari V, Bhatia S (2019) Potential gains of screening family members of suspected coronary artery disease: a pilot study. Int J Prev Med 10:148","journal-title":"Int J Prev Med"},{"key":"3794_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.4103\/ijpvm.IJPVM_35_19","volume":"10","author":"M Javadi","year":"2019","unstructured":"Javadi M, Jamalzehi A, Gerami H, Hosseini SK, Maljaei MB, Eslami M et al (2019) Association between dietary intakes of tea, coffee, and soft drinks in patients undergoing coronary angiography with coronary artery stenosis. Int J Prev Med 10:172","journal-title":"Int J Prev Med"},{"issue":"7","key":"3794_CR4","first-page":"1041","volume":"12","author":"L Horv\u00e1th","year":"2022","unstructured":"Horv\u00e1th L, N\u00e9meth N, Feh\u00e9r G, K\u00edv\u00e9s Z, Endrei D, Boncz I (2022) Epidemiology of peripheral artery disease: narrative review. Life (Basel) 12(7):1041","journal-title":"Life (Basel)"},{"issue":"2","key":"3794_CR5","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2991\/jegh.k.201217.001","volume":"11","author":"U Ralapanawa","year":"2021","unstructured":"Ralapanawa U, Sivakanesan R (2021) Epidemiology and the magnitude of coronary artery disease and acute coronary syndrome: a narrative review. J Epidemiol Glob Health 11(2):169\u2013177","journal-title":"J Epidemiol Glob Health"},{"issue":"1","key":"3794_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12872-018-0761-0","volume":"18","author":"G Zhang","year":"2018","unstructured":"Zhang G, Yu C, Zhou M, Wang L, Zhang Y, Luo L (2018) Burden of Ischaemic heart disease and attributable risk factors in China from 1990 to 2015: findings from the global burden of disease 2015 study. BMC Cardiovasc Disord 18(1):18","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"3794_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ijcard.2014.04.096","volume":"174","author":"AN Nowbar","year":"2014","unstructured":"Nowbar AN, Howard JP, Finegold JA, Asaria P, Francis DP (2014) 2014 global geographic analysis of mortality from ischaemic heart disease by country, age and income: statistics from World Health Organisation and United Nations. Int J Cardiol 174(2):293\u2013298","journal-title":"Int J Cardiol"},{"issue":"10","key":"3794_CR8","first-page":"e30119","volume":"14","author":"D Adhikary","year":"2022","unstructured":"Adhikary D, Barman S, Ranjan R, Stone H (2022) A systematic review of major cardiovascular risk factors: a growing global health concern. Cureus 14(10):e30119","journal-title":"Cureus"},{"issue":"6","key":"3794_CR9","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/CIRCRESAHA.117.308903","volume":"121","author":"P Joseph","year":"2017","unstructured":"Joseph P, Leong D, McKee M, Anand SS, Schwalm JD, Teo K et al (2017) Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. Circ Res 121(6):677\u2013694","journal-title":"Circ Res"},{"issue":"7","key":"3794_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/14779072.2018.1484281","volume":"16","author":"L Seoane","year":"2018","unstructured":"Seoane L, Cort\u00e9s M, ArisCancela ME, Furmento J, Baranchuk A, Conde D (2018) Rivaroxaban in the cardiovascular world: a direct anticoagulant useful to prevent stroke and venous and arterial thromboembolism. Expert Rev Cardiovasc Ther 16(7):501\u2013514","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"10117","key":"3794_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","volume":"391","author":"SS Anand","year":"2018","unstructured":"Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P et al (2018) Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 391(10117):219\u2013229","journal-title":"Lancet"},{"issue":"13","key":"3794_CR12","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1177\/2047487320913380","volume":"27","author":"S Petersohn","year":"2020","unstructured":"Petersohn S, Pouwels X, Ramaekers B, Ten Cate-Hoek A, Joore M (2020) Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study. Eur J Prev Cardiol 27(13):1354\u20131365","journal-title":"Eur J Prev Cardiol"},{"key":"3794_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"1","key":"3794_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/00005650-200301000-00007","volume":"41","author":"CF Chiou","year":"2003","unstructured":"Chiou CF, Hay JW, Wallace JF, Bloom BS, Neumann PJ, Sullivan SD et al (2003) Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care 41(1):32\u201344","journal-title":"Med Care"},{"key":"#cr-split#-3794_CR15.1","unstructured":"The Campbell and Cochrane Economics Methods Group (CCEMG) & Evidence for Policy and Practice Information and Coordinating Centre (EPPI-Centre) (2019) [Internet]"},{"key":"#cr-split#-3794_CR15.2","unstructured":"[cited 2022 Aug 9]. CCEMG - EPPI-Centre Cost Converter. Available from: https:\/\/eppi.ioe.ac.uk\/costconversion\/"},{"issue":"5","key":"3794_CR16","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/ehjqcco\/qcac054","volume":"9","author":"A Lamy","year":"2023","unstructured":"Lamy A, Eikelboom J, Tong W, Yuan F, Bangdiwala SI, Bosch J et al (2023) The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial. Eur Heart J Qual Care Clin Outcomes 9(5):502\u2013510","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"1","key":"3794_CR17","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1080\/13696998.2021.1997024","volume":"24","author":"JA Spoorendonk","year":"2021","unstructured":"Spoorendonk JA, Briere JB, Bowrin K, Millier A, Coppens M, Tempelaar S et al (2021) Clinical implications and cost-effectiveness analysis of rivaroxaban in patients with coronary artery disease or peripheral arterial disease in the Netherlands. J Med Econ 24(1):1231\u20131239","journal-title":"J Med Econ"},{"issue":"11","key":"3794_CR18","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1093\/cvr\/cvz278","volume":"116","author":"MR Cowie","year":"2020","unstructured":"Cowie MR, Lamy A, Levy P, Mealing S, Millier A, Mernagh P et al (2020) Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease. Cardiovasc Res 116(11):1918\u20131924","journal-title":"Cardiovasc Res"},{"issue":"7","key":"3794_CR19","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1007\/s12325-020-01398-8","volume":"37","author":"E Soini","year":"2020","unstructured":"Soini E, Virtanen O, V\u00e4\u00e4t\u00e4inen S, Briere JB, Bowrin K, Millier A (2020) Cost-effectiveness of coronary and peripheral artery disease antithrombotic treatments in Finland. Adv Ther 37(7):3348\u20133369","journal-title":"Adv Ther"},{"issue":"5","key":"3794_CR20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40261-021-01023-8","volume":"41","author":"P Ferrara","year":"2021","unstructured":"Ferrara P, Cortesi PA, Di Laura D, Maggioni AP, Mantovani LG (2021) Cost-effectiveness analysis of rivaroxaban plus aspirin compared with aspirin alone in patients with coronary and peripheral artery diseases in Italy. Clin Drug Investig 41(5):459\u2013468","journal-title":"Clin Drug Investig"},{"issue":"8","key":"3794_CR21","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1177\/2047487318817910","volume":"26","author":"E Zomer","year":"2019","unstructured":"Zomer E, Si S, Hird TR, Liew D, Owen AJ, Tonkin A et al (2019) Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: an Australian healthcare perspective. Eur J Prev Cardiol 26(8):858\u2013868","journal-title":"Eur J Prev Cardiol"},{"key":"3794_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijcard.2018.06.091","volume":"270","author":"Z Ademi","year":"2018","unstructured":"Ademi Z, Zomer E, Tonkin A, Liew D (2018) Cost-effectiveness of rivaroxaban and aspirin compared to aspirin alone in patients with stable cardiovascular disease: an Australian perspective. Int J Cardiol 270:54\u201359","journal-title":"Int J Cardiol"},{"key":"3794_CR23","doi-asserted-by":"publisher","first-page":"921387","DOI":"10.3389\/fphar.2022.921387","volume":"13","author":"T Feng","year":"2022","unstructured":"Feng T, Zheng Z, Gao S, Xu J, Cao P, Jia H et al (2022) Cost-effectiveness analysis of rivaroxaban in chinese patients with stable cardiovascular disease. Front Pharmacol 13:921387","journal-title":"Front Pharmacol"},{"issue":"3","key":"3794_CR24","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10557-020-07059-w","volume":"35","author":"MC Lee","year":"2021","unstructured":"Lee MC, Liao CT, Toh HS, Chou CC, Chang WT, Chen ZC et al (2021) Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases. Cardiovasc Drugs Ther 35(3):539\u2013547","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"3794_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40256-023-00620-6","volume":"24","author":"A Lamy","year":"2024","unstructured":"Lamy A, Eikelboom J, Tong W, Yuan F, Bangdiwala SI, Bosch J et al (2024) The cost-effectiveness of rivaroxaban plus aspirin compared with aspirin alone in the COMPASS trial: a us perspective. Am J Cardiovasc Drugs 24(1):117\u2013127","journal-title":"Am J Cardiovasc Drugs"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03794-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03794-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03794-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T08:07:52Z","timestamp":1736410072000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03794-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3794"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03794-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"assertion":[{"value":"5 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research Ethics Committee of Iran University of Medical Sciences (IR.IUMS.REC.1402.1051).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}